Interview with Philippe van der Hofstadt, Founder & CEO, B & C Group
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Address: Watson & Crick Hill, Rue Granbonpré 11, B-1348 Mont-Saint-Guibert,Belgium
Tel: +32 (0)10 237 444
Web: http://www.bnc-group.com/
B & C Group is a Packaging & Logistics Company solely dedicated to (Pre)Clinical Research.
Established in 1999 as a niche provider of ground transport for batched frozen specimen shipments, B & C was the first company of its kind to offer full specimen tracking and on-site data cleaning. Today we offer a unique combination of logistics services through our network.
B & C Group adds value to your clinical research logistics process by its unique approach on centralization and integration combined with experience, expertise and geographic reach.
Since January 2009, B & C Group has relocated its two sites in Mechelen and Wavre to the former Eli Lilly IMP Packaging & distribution facility in Mont-St-Guibert (South of Brussels – Belgium).
B & C provides integrated Packaging and Logistics services for the Clinical Trials sponsored or supported by:
Pharmaceutical Companies
Biotechnology Companies
Central Laboratories
Contract Research Organizations
Academic Institutions
Investigational Sites
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Writing in DIA’s Global Forum magazine for June 2024, the organization’s Vedran Raguz reviews some of the key takeaways from DIA Europe 2024, namely the need for increased collaboration, alignment…
Founded in 1996 to coordinate and promote HIV vaccine development, IAVI has had a major impact across HIV vaccine development efforts, capacity building in low- and middle-income countries, advocacy work,…
PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient…
Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its…
A new piece in the January 2023 edition of DIA’s Global Forum magazine lays out how a new coalition aims to transform the landscape for rare disease treatments in Europe…
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Pfizer’s David Isom and Monica Mihedji, writing in the November 2023 edition of the DIA’s Global Forum magazine, examine how the European Medicines Agency is attempting to integrate the use…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
The European Coalition for Access to Comprehensive Genomic Profiling (ECGP) is a new initiative made up of industry association the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), molecular diagnostics firms Exact…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is…
See our Cookie Privacy Policy Here
